查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1625024

2024 年至 2031 年按技术、应用、最终用户、服务类型和地区划分的下一代定序 (NGS) 服务市场

Next-Generation Sequencing Services Market By Technology, Application, End-User (Hospitals and Clinics, Contract Research Organizations ), Service Type, & Region for 2024-2031
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

次世代定序 (NGS) 服务市场评估-2024-2031

对次世代定序 (NGS) 服务的需求不断增长，很大程度上是由于其对个人化医疗和诊断的颠覆性影响。 NGS改变了医疗保健提供者诊断和治疗疾病的方式，特别是在肿瘤学、遗传疾病和传染病领域。 NGS 可以对整个基因组或选定区域进行快速可靠的测序，从而能够检测出可以为有针对性的药物提供资讯的基因变异，从而使市场在2024 年增长95%。超过33 亿美元，达到2031年估值约183.5亿美元。

对预防性医疗保健的日益关注推动了对 NGS 服务的需求。随着医疗保健系统转向疾病检测和预防，NGS 提供了全面的基因组筛检，以识别特定疾病的易感性并实现早期干预。这在药物基因组学领域尤其重要，因为NGS可用于预测个体对特定药物的反应，预计2024年至2031年期间的复合年增长率为21.25%。

次世代定序 (NGS) 服务市场：定义/概述

次世代定序 (NGS) 服务是一种先进的基因组技术，可以快速定序 DNA 或 RNA，以大规模评估遗传讯息。 NGS 服务为医学研究、诊断、药物发现和个人化医疗等广泛应用所需的基因变异、突变和基因表现提供了关键见解。

次世代定序（NGS）服务有许多应用，包括遗传学、医学诊断和个人化医疗。最常见的用途之一是基因检测，它可以识别遗传的基因异常、突变和疾病倾向。 NGS 能够对整个基因组或特定区域进行快速、高通量测序，揭示有关癌症、囊性纤维化和心血管疾病等疾病背后的基因突变的大量资讯。

次世代定序 (NGS) 服务的未来应用预计将改变医疗保健的许多方面，包括个人化医疗和基因组学。最有前景的应用之一是癌症诊断和治疗，其中NGS可以提供​​详细的肿瘤分析并找出导致癌症生长的特定基因异常。

推动次世代定序 (NGS) 服务市场采用的关键因素有哪些？

次世代定序 (NGS) 服务的采用主要由个人化医疗应用的增加、基因组研究的进步以及定序技术成本的下降所推动。这些特性促进了NGS在各种医疗保健和生命科学应用中的使用。个人化医疗是广泛采用NGS服务的主要驱动力。根据美国食品药物管理局（FDA）的数据，截至2022年，过去五年核准的新药中超过25%是个人化药物，其中许多是使用NGS技术开发的。

根据美国国家人类基因组研究所（NHGRI）预测，到2022年，人类基因组定序成本预计将下降10万倍，从2001年的约1亿美元降至1,000美元以下。另一个重要因素是NGS在癌症研究和治疗上的应用日益广泛。美国国家癌症研究所的癌症基因组图谱 (TCGA) 使用 NGS 技术评估了 33 种癌症类型的 20,000 多例原发性癌症和匹配的正常样本。在肿瘤学领域如此广泛的应用正在推动NGS服务产业向前发展。

伦理和法律问题是否阻碍了次世代定序（NGS）服务市场的发展？

伦理和法律考量对次世代定序（NGS）服务领域的扩展有重大影响。主要的道德考虑之一是隐私和基因数据的处理。 NGS服务涉及人类基因组定序，会产生敏感的个人资讯，如果不加以妥善保护，这些资讯可能会被滥用。未经授权存取基因数据引发了对滥用的担忧，例如就业和保险中的基因歧视。

法律问题也对NGS服务业务构成了障碍，特别是在法规合规性和智慧财产权方面。随着NGS技术的进步，管理基因组资讯使用的法律架构也不断发展。各国政策不一致阻碍了国际研究合作并限制了市场成长。公司必须遵守复杂的专利法规，特别是有关基因组定序和 NGS 相关技术所有权的法规。此外，围绕人类基因或特定基因组序列专利的法律纠纷可能会抑制创新并限制获得关键的NGS服务。

目录

第 1 章 全球次世代定序 (NGS) 服务市场：简介

  • 市场定义
  • 市场区隔
  • 调查安排
  • 先决条件
  • 限制

第 2 章：经过验证的市场研究方法

  • 资料探勘
  • 数据三角测量
  • 由下而上的方法
  • 自上而下的方法
  • 调查流程
  • 产业专家的重要见解
  • 资料来源

第 3 章执行摘要

    市场概况
  • 生态製图
  • 绝对的获利机会
  • 市场吸引力
  • 全球次世代定序 (NGS) 服务市场：区域分析（CAGR）
  • 全球次世代定序 (NGS) 服务市场按服务类型划分
  • 全球次世代定序 (NGS) 服务市场（按技术划分）
  • 全球下一代定序 (NGS) 服务市场（按最终用户划分）
  • 全球次世代定序 (NGS) 服务市场（按应用）
  • 未来市场机会
  • 全球市场细分
  • 产品生命线

第 4 章。
  • 全球新一代定序 (NGS) 服务的发展
  • 驱动程式
  • 阻碍因素
  • 机会
  • 波特五力模型
  • 价值链分析
  • 价格分析
  • 宏观经济分析

5. 全球次世代定序 (NGS) 服务市场（依服务类型）

  • 概述 外显子定序
  • 标靶重定序与客製化基因组
  • 全基因组定序与从头定序，RNA-Seq
  • 其他
6. 全球次世代定序 (NGS) 服务市场（按技术）
  • 概述 合成定序
  • 离子半导体定序
  • 单分子即时定序 奈米孔定序

7. 全球下一代定序 (NGS) 服务市场（按最终用户划分）

  • 概述
  • 学术与政府机构、研究中心
  • 医院和诊所
  • 製药和生技公司
  • 其他

8. 全球次世代定序 (NGS) 服务市场（按应用）

  • 概述
  • 诊断
  • 药物研发
  • 生物标记的发现
  • 农业与动物研究
  • 其他

9. 全球次世代定序 (NGS) 服务市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家
    亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲国家
  • 中东和非洲
    • 阿拉伯联合大公国
    • 沙乌地阿拉伯
    • 南非
    • 其他中东和非洲地区

10. 全球次世代定序 (NGS) 服务市场：竞争格局

  • 概述
  • 各公司的市场排名
  • 重大进展
  • 公司地理分布
  • 公司产业足迹
  • ACE 矩阵

第 11 章 公司简介

  • Eurofins Scientific
  • illumina, Inc.
  • BGI genomics Co., Ltd.
  • Perkinelmer Inc.
  • Macrogen, Inc.
  • Qiagen N.V.
  • Genewiz
  • Personalis, Inc.
  • Takara Bio Inc.
  • LGC Science Group Holdings Limited

第 12 章 经过验证的市场研究

    关于 VERIFIED MARKET RESEARCH
  • 动态资料视觉化
简介目录
Product Code: 25919

Next-Generation Sequencing (NGS) Services Market Valuation - 2024-2031

The growing demand for next-generation sequencing (NGS) services is largely due to its disruptive impact on personalized medicine and diagnostics. NGS has transformed how healthcare providers approach disease diagnosis and therapy, especially in oncology, genetic disorders, and infectious diseases. NGS enables the speedy and reliable sequencing of complete genomes or select areas allowing the detection of genetic alterations that can inform targeted medicines, hence improving patient outcomes by enabling the market to surpass a revenue of USD 9.53 Billion valued in 2024 and reach a valuation of aroundUSD 18.35 Billion by 2031.

The increased emphasis on preventative healthcare is driving up the demand for NGS services. As healthcare systems turn toward disease detection and prevention, NGS provides comprehensive genomic screening, identifying predispositions to specific ailments and allowing for earlier interventions. This is especially crucial in the field of pharmacogenomics where NGS is used to anticipate how individuals will react to specific pharmaceuticals, hence reducing bad drug responses by enabling the market to grow at aCAGR of 21.25% from 2024 to 2031.

Next Generation Sequencing (NGS) Services Market: Definition/ Overview

Next Generation Sequencing (NGS) services are advanced genomic technologies that enable quick sequencing of DNA or RNA to evaluate genetic information on a massive scale. NGS services give critical insights into genetic variants, mutations, and gene expression which are required for a wide range of applications including medical research and diagnostics, drug discovery, and personalized medicine.

Next Generation Sequencing (NGS) services have numerous uses including genetics, medical diagnostics, and customized medicine. One of the most common applications is genetic testing, which identifies inherited genetic abnormalities, mutations, and disease propensity. NGS enables quick, high-throughput sequencing of entire genomes or particular areas revealing extensive information about genetic variants that contribute to disorders including cancer, cystic fibrosis, and cardiovascular disease.

The future usage of next-generation sequencing (NGS) services is expected to transform numerous aspects of healthcare including personalized medicine and genomics. One of the most promising applications is cancer diagnosis and treatment where NGS may give detailed tumor profiling and pinpoint particular genetic abnormalities that cause cancer growth.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

What are the Key Drivers Promoting the Adoption of the Next-Generation Sequencing (NGS) Services Market?

The use of next-generation sequencing (NGS) services is being pushed primarily by increased applications in personalized medicine, advances in genomic research, and lower sequencing technology costs. These characteristics are driving the usage of NGS in a variety of healthcare and life sciences applications. Personalized medicine is a primary driver of NGS service uptake. According to the U.S. Food and Drug Administration (FDA), as of 2022, more than 25% of new pharmaceuticals approved in the past five years were personalized medicines many of which were developed using NGS technologies.

According to the National Human Genome Research Institute (NHGRI), the cost of sequencing a human genome has dropped from approximately USD 100 Million in 2001 to less than $1,000 in 2022, a 100,000-fold decrease. Another key factor is the growing application of NGS in cancer research and treatment. The National Cancer Institute's Cancer Genome Atlas (TCGA) used NGS technology to evaluate over 20,000 primary cancers and matched normal samples from 33 cancer types. This widespread application in oncology is driving the NGS services industry forward.

Will the Ethical and Juridical Concerns Hamper the Next Generation Sequencing (NGS) Services Market?

Ethical and legal considerations have a substantial impact on the expansion of the next generation sequencing (NGS) services sector. One of the main ethical considerations is privacy and the handling of genetic data. Because NGS services include the sequencing of human genomes, sensitive personal information is generated which could be misused if not appropriately protected. Unauthorized access to genetic data raises issues about misuse such as genetic discrimination in employment or insurance.

Legal problems also pose hurdles for the NGS services business, particularly in terms of regulatory compliance and intellectual property rights. As NGS technology progresses, the legal framework governing genomic information use continues to evolve. Inconsistent policies across countries hamper international collaborations and limit market growth. Companies must manage complex patent regulations, particularly those governing ownership of genomic sequences and NGS-related technologies. Furthermore, legal battles over the patenting of human genes or specific genomic sequences can stifle innovation and restrict access to critical NGS services.

Category-Wise Acumens

How Will the Increasing Popularity of Whole Genome Sequencing Drive the Adoption of Next-Generation Sequencing (NGS) Services?

Whole genome sequencing (WGS) is a dominating technology in the next-generation sequencing (NGS) services industry due to its comprehensive nature and wide range of applications across industries. The ability to study genetic variations, mutations, structural changes, and functional elements across the entire genome providing insights into complex biological processes, disease mechanisms, and personalized medicine applications is increasing the use of WGS by researchers, clinicians, and organizations.

In addition, its involvement in discovering novel genetic markers, biomarkers, disease-causing mutations, and therapeutic targets for expanding our understanding of genetic features, hereditary diseases, complex disorders, and genetic predispositions will further accelerate the usage of WGS. In clinical diagnostics and healthcare, WGS is critical for genetic testing, illness diagnosis, and tailored medication. This allows clinicians to identify disease-causing mutations, analyze genetic risk factors, diagnose uncommon genetic illnesses, predict therapy responses, and adapt medicines to individual genomic profiles.

In What Ways are Hospitals and Clinics Driving the Growth of the Next-Generation Sequencing (NGS) Services Market?

The increase in demand for NGS services in hospitals and clinics for a wide range of clinical diagnostic applications including prenatal screening, pharmacogenomics, cancer genomics, rare illness detection, and infectious disease testing is a market profitable factor. NGS enables clinicians to perform the necessity for doctors to conduct complete genomic profiling of patient samples and find genetic mutations, structural variants, and biomarkers to provide accurate prognosis, treatment response, and disease risk data is expected to drive market expansion.

By incorporating genomic information into clinical decision-making, hospitals and clinics can improve treatment outcomes, reduce adverse medication responses, and increase patient happiness and quality of life. Genomic medicine research is widely conducted at hospitals and university medical institutes to improve scientific understanding of hereditary illnesses, molecular pathways, and therapeutic targets. NGS services contribute significantly to genomic research projects by facilitating large-scale DNA sequencing, genome-wide association studies (GWAS), and functional genomics experiments.

Country/Region-wise Acumens

Will the Development of Precision and Tailored Treatments Drive the Market in the North American Region?

North America dominates the next generation sequencing (NGS) services market owing to its advanced healthcare infrastructure and major investments in precision medicine. The Precision Medicine Initiative, initiated by the US government in 2015 with an initial USD 215 Million commitment, has been a significant driver of NGS uptake. The National Institutes of Health's (NIH) "All of Us" Research Program, which is part of this project, seeks to collect genetic data from one million Americans and has already registered over 500,000 people as of 2023.

The NIH's Undiagnosed Diseases Network has employed NGS to diagnose 35% of cases, demonstrating the technology's utility. Furthermore, the Centers for Medicare & Medicaid Services (CMS) enhanced coverage for NGS-based diagnostic tests for individuals with hereditary ovarian or breast cancer in 2020, possibly benefiting up to 100,000 Medicare patients per year. This coverage expansion is projected to dramatically increase the use of NGS services in clinical settings. According to the Centers for Disease Control and Prevention (CDC), more than 1.8 million SARS-CoV-2 genomes will have been sequenced in the United States by 2022, demonstrating the importance of NGS in disease surveillance and pandemic response.

Will the Increasing Demand for Genomic Therapeutics and Whole-Genome Sequencing Drive the Market in the Asia Pacific Region?

The Asia Pacific region is seeing the highest growth in the next generation sequencing (NGS) services market owing to increased demand for genomic therapies and whole-genome sequencing. Significant government funding, increased research activity, and the region's expanding prevalence of genetic illnesses all contribute to its rapid growth. This investment has already paid off with the number of whole-genome sequencing studies in China increasing by 120% between 2015 and 2020, according to the National Center for Biotechnology Information (NCBI).

Another important factor is the region's rising prevalence of genetic diseases. According to the World Health Organization (WHO), the incidence of genetic disorders in Asia is 53.5 per 1,000 live births which is higher than the global average of 39.7. This has resulted in an increased demand for genetic testing and tailored medicine. Since 2017, the South Korean government's Genome Technology to Business Translation Program has invested USD 70 Million in 100 genomics-based startups. Australia's Genomes Health Futures Mission which is part of the Medical Research Future Fund has committed AU$500 million over ten years to genomes research, with AU$150 million already funded by 2023.

Competitive Landscape

The Next Generation Sequencing (NGS) Services Market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the next-generation sequencing (NGS) services market include:

Quest Diagnostics Incorporated

ARUP Laboratories

Applied Biological Materials, Inc.

Novogene Co, Ltd.

Azenta Life Sciences (GENEWIZ)

NanoString

Illumina, Inc.

PacBio

Veritas

BGI (Beijing Genomics Institute)

Gene by Gene Ltd.

Lucigen Corporation

Latest Developments

In August 2022, A market leader in clinical diagnostics and life science research introduced a line of type 1 antibodies that prevent the drug evolocumab (Repatha(R)) from binding to its intended target, the human proprotein convertase subtilisin/Kexin type 9 (PCSK9), which has been linked to cholesterol control. These recombinant antibodies with predetermined sequences can be employed to develop highly sensitive and selective evolocumab and biosimilar-specific pharmacokinetic (PK) and anti-drug antibody (ADA) assays.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET

  • 1.1 Market Definition
  • 1.2 Market Segmentation
  • 1.3 Research Timelines
  • 1.4 Assumptions
  • 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data Mining
  • 2.2 Data Triangulation
  • 2.3 Bottom-Up Approach
  • 2.4 Top-Down Approach
  • 2.5 Research Flow
  • 2.6 Key Insights from Industry Experts
  • 2.7 Data Sources

3 EXECUTIVE SUMMARY

  • 3.1 Market Overview
  • 3.2 Ecology Mapping
  • 3.3 Absolute Market Opportunity
  • 3.4 Market Attractiveness
  • 3.5 Global Next-Generation Sequencing (NGS) Services Market Geographical Analysis (CAGR %)
  • 3.6 Global Next-Generation Sequencing (NGS) Services Market, By Service Type (USD Million)
  • 3.7 Global Next-Generation Sequencing (NGS) Services Market, By Technology (USD Million)
  • 3.8 Global Next-Generation Sequencing (NGS) Services Market, By End-Users (USD Million)
  • 3.9 Global Next-Generation Sequencing (NGS) Services Market, By Application (USD Million)
  • 3.10 Future Market Opportunities
  • 3.11 Global Market Split
  • 3.12 Product Life Line

4 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET OUTLOOK

  • 4.1 Global Next-Generation Sequencing (NGS) Services Evolution
  • 4.2 Drivers
    • 4.2.1 Driver 1
    • 4.2.2 Driver 2
  • 4.3 Restraints
    • 4.3.1 Restraint 1
    • 4.3.2 Restraint 2
  • 4.4 Opportunities
    • 4.4.1 Opportunity 1
    • 4.4.2 Opportunity 2
  • 4.5 Porters Five Force Model
  • 4.6 Value Chain Analysis
  • 4.7 Pricing Analysis
  • 4.8 Macroeconomic Analysis

5 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET, BY SERVICE TYPE

  • 5.1 Overview
  • 5.2 Exome Sequencing
  • 5.3 Targeted Resequencing & Custom Gene Panels
  • 5.4 Whole-Genome Sequencing & De Novo Sequencing, RNA-Seq
  • 5.5 Others

6 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET, BY TECHNOLOGY

  • 6.1 Overview
  • 6.2 Sequencing By Synthesis
  • 6.3 Ion Semiconductor Sequencing
  • 6.4 Single-Molecule Real-Time Sequencing
  • 6.5 Nanopore Sequencing

7 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET, BY END-USERS

  • 7.1 Overview
  • 7.2 Academic & Government Institutes and Research Centers
  • 7.3 Hospitals & Clinics
  • 7.4 Pharmaceutical & Biotechnology Companies
  • 7.5 Others

8 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET, BY APPLICATION

  • 8.1 Overview
  • 8.2 Diagnostics
  • 8.3 Drug Discovery
  • 8.4 Biomarker Discovery
  • 8.5 Agriculture & Animal Research
  • 8.6 Others

9 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET, BY GEOGRAPHY

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 U.K.
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of Latin America
  • 9.6 Middle-East and Africa
    • 9.6.1 UAE
    • 9.6.2 Saudi Arabia
    • 9.6.3 South Africa
    • 9.6.4 Rest of Middle-East and Africa

10 GLOBAL NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET COMPETITIVE LANDSCAPE

  • 10.1 Overview
  • 10.2 Company Market Ranking
  • 10.3 Key Developments
  • 10.4 Company Regional Footprint
  • 10.5 Company Industry Footprint
  • 10.6 ACE Matrix

11 COMPANY PROFILES

  • 11.1 Eurofins Scientific
    • 11.2.1 Company Overview
    • 11.2.2 Company Insights
    • 11.2.3 Product Benchmarking
    • 11.2.4 Key Development
    • 11.2.5 Winning Imperatives
    • 11.2.6 Current Focus & Strategies
    • 11.2.7 Threat from Competition
    • 11.2.8 SWOT Analysis
  • 11.2 illumina, Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Company Insights
    • 11.3.3 Product Benchmarking
    • 11.3.4 Key Development
    • 11.3.5 Winning Imperatives
    • 11.3.6 Current Focus & Strategies
    • 11.3.7 Threat from Competition
    • 11.3.8 SWOT Analysis
  • 11.3 BGI genomics Co., Ltd.
    • 11.3.1 Company Overview
    • 11.3.2 Company Insights
    • 11.3.3 Product Benchmarking
    • 11.3.4 Key Development
    • 11.3.5 Winning Imperatives
    • 11.3.6 Current Focus & Strategies
    • 11.3.7 Threat from Competition
    • 11.3.8 SWOT Analysis
  • 11.4 Perkinelmer Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Company Insights
    • 11.4.3 Product Benchmarking
    • 11.4.4 Key Development
    • 11.4.5 Winning Imperatives
    • 11.4.6 Current Focus & Strategies
    • 11.4.7 Threat from Competition
    • 11.4.8 SWOT Analysis
  • 11.5 Macrogen, Inc.
    • 11.5.1 Company Overview
    • 11.5.2 Company Insights
    • 11.5.3 Product Benchmarking
    • 11.5.4 Key Development
    • 11.5.5 Winning Imperatives
    • 11.5.6 Current Focus & Strategies
    • 11.5.7 Threat from Competition
    • 11.5.8 SWOT Analysis
  • 11.6 Qiagen N.V.
    • 11.6.1 Company Overview
    • 11.6.2 Company Insights
    • 11.6.3 Product Benchmarking
    • 11.6.4 Key Development
    • 11.6.5 Winning Imperatives
    • 11.6.6 Current Focus & Strategies
    • 11.6.7 Threat from Competition
    • 11.6.8 SWOT Analysis
  • 11.7 Genewiz
    • 11.7.1 Company Overview
    • 11.7.2 Company Insights
    • 11.7.3 Product Benchmarking
    • 11.7.4 Key Development
    • 11.7.5 Winning Imperatives
    • 11.7.6 Current Focus & Strategies
    • 11.7.7 Threat from Competition
    • 11.7.8 SWOT Analysis
  • 11.8 Personalis, Inc.
    • 11.8.1 Company Overview
    • 11.8.2 Company Insights
    • 11.8.3 Product Benchmarking
    • 11.8.4 Key Development
    • 11.8.5 Winning Imperatives
    • 11.8.6 Current Focus & Strategies
    • 11.8.7 Threat from Competition
    • 11.8.8 SWOT Analysis
  • 11.9 Takara Bio Inc.
    • 11.9.1 Company Overview
    • 11.9.2 Company Insights
    • 11.9.3 Product Benchmarking
    • 11.9.4 Key Development
    • 11.9.5 Winning Imperatives
    • 11.9.6 Current Focus & Strategies
    • 11.9.7 Threat from Competition
    • 11.9.8 SWOT Analysis
  • 11.10 LGC Science Group Holdings Limited
    • 11.10.1 Company Overview
    • 11.10.2 Company Insights
    • 11.10.3 Product Benchmarking
    • 11.10.4 Key Development
    • 11.10.5 Winning Imperatives
    • 11.10.6 Current Focus & Strategies
    • 11.10.7 Threat from Competition
    • 11.10.8 SWOT Analysis

12 VERIFIED MARKET RESEARCH

  • 12.1 About Verified Market Research
  • 12.2 Dynamic Data Visualization